Fluticasone furoate: all 116 studies that test it

Page 1 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of ExacerbationRecruitingNCT07192016Phase 4
• Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass ExposureRecruitingNCT06571942Phase 4
• Role of Lung Function for Exercise Capacity in Well-trained IndividualsRecruitingNCT06077019Not applicable
• U-LABA/ICS Effects on Exercise Performance, VilanterolRecruitingNCT06066606Not applicable
• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaRecruitingNCT05757102Phase 3
• Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaActive, not recruitingNCT06372496Phase 4Results posted
• To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPDCompletedNCT05535972Phase 4Results posted
• Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaCompletedNCT04937387Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT04923347Phase 4Results posted
• Evaluation of Triple Therapy Using Magnetic Resonance Imaging in AsthmaActive, not recruitingNCT04651777Phase 3Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478696Phase 4Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478683Phase 4Results posted
• A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03474081Phase 4Results posted
• INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignCompletedNCT03467425Phase 4Results posted
• Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a YearCompletedNCT02889809Phase 4Results posted
• Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02729051Phase 3Results posted
• A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.CompletedNCT02712047Phase 2Results posted
• Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary DiseaseCompletedNCT02573870Phase 2Results posted
• Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With AsthmaCompletedNCT02502734Phase 3Results posted
• Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With AsthmaCompletedNCT02483975Phase 3Results posted
• A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaCompletedNCT02446418Phase 3Results posted
• Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic ComponentCompletedNCT02164539Phase 2Results posted
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02164513Phase 3Results posted
• Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105974Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese SubjectsCompletedNCT02094937Phase 3Results posted
• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01957150Phase 4Results posted
• To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With AsthmaCompletedNCT01808339Phase 2Results posted
• An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaCompletedNCT01706198Phase 3Results posted
• RELOVAIR® Lung Deflation StudyCompletedNCT01691885Phase 3Results posted
• An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.CompletedNCT01686633Phase 3Results posted
• Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic RhinitisCompletedNCT01630135Phase 3Results posted
• Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic RhinitisCompletedNCT01622231Phase 3Results posted
• A Dose-ranging Study of Fluticasone Furoate (FF)CompletedNCT01563029Phase 2Results posted
• A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551758Phase 3Results posted
• Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD StudyCompletedNCT01453023Phase 2Results posted
• Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With AsthmaCompletedNCT01436110Phase 3Results posted
• Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With AsthmaCompletedNCT01436071Phase 3Results posted
• Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and AdolescentsCompletedNCT01431950Phase 3Results posted
• A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPDCompletedNCT01376245Phase 3Results posted
• A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))CompletedNCT01342913Phase 3Results posted
• A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPDCompletedNCT01336608Phase 3Results posted
• Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic PatientsCompletedNCT01332292Phase 2Results posted
• Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01323634Phase 3Results posted
• Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01323621Phase 3Results posted
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01313676Phase 3Results posted
• A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic RhinitisCompletedNCT01279057Phase 3Results posted
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic RhinitisCompletedNCT01231464Phase 3Results posted
• Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and AdolescentsCompletedNCT01159912Phase 3Results posted
• Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic ResponseCompletedNCT01128595Phase 2Results posted
• Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic ResponseCompletedNCT01128569Phase 2Results posted
• Asthma Exacerbation StudyCompletedNCT01086384Phase 3Results posted
• Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety StudyCompletedNCT01018186Phase 3Results posted
• Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid DiseaseTerminatedNCT01013701Phase 4Results posted
• Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy SymptomsCompletedNCT01007253Phase 4Results posted
• Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic RhinitisCompletedNCT00997620Phase 4Results posted
• Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye SymptomsCompletedNCT00891436Phase 4Results posted
• Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With AllergenCompletedNCT00791973Phase 4Results posted
• Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of AsthmaCompletedNCT00766090Phase 2Results posted
• A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) RhinitisCompletedNCT00730756Phase 2Results posted
• A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic RhinitisCompletedNCT00682643Phase 4Results posted
• A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic RhinitisCompletedNCT00609674Phase 4Results posted
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.CompletedNCT00603746Phase 2Results posted
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.CompletedNCT00603382Phase 2Results posted
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.CompletedNCT00603278Phase 2Results posted
• Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea SyndromeCompletedNCT00603044Phase 4Results posted
• Intranasal Steroids and Oxymetazoline in Allergic RhinitisCompletedNCT00584987Phase 4Results posted
• Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.CompletedNCT00570492Phase 4Results posted
• Fluticasone Furoate Nasal Spray Versus Oral FexofenadineCompletedNCT00502775Phase 4Results posted
• Fluticasone Furoate Nasal Spray Versus Oral FexofenadineCompletedNCT00435461Phase 4Results posted
• Fluticasone Nasal Spray Patient Preference StudyCompletedNCT00398476Phase 3Results posted
• Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)CompletedNCT00289198Phase 3Results posted
• Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor RhinitisCompletedNCT00118703Phase 3Results posted
• Study Of Adults And Adolescents With Vasomotor RhinitisCompletedNCT00117325Phase 3Results posted
• Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover StudyCompletedNCT06905483Phase 4
• Medical vs Surgical Treatment in OSA Among ChildrenStatus unknownNCT05651750Phase 4
• Effect of Fluticasone Furoate/Vilanterol on EIA in AdolescentsCompletedNCT04750603Phase 4
• Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness StudyWithdrawnNCT03949842Phase 4
• Effect of Fluticasone Furoate on Methacholine ChallengeCompletedNCT03898466Phase 4
• Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone FuroateCompletedNCT03739294Phase 2
• Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled AsthmaWithdrawnNCT03376932Phase 3
• The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on AsthmaWithdrawnNCT03363191Phase 4
• Effect of Vilanterol on Methacholine Challenge ResultsCompletedNCT03315000Phase 4
• INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and OlodaterolCompletedNCT03152149Phase 4
• A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese SubjectsCompletedNCT02837380Phase 1
• A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)WithdrawnNCT02731846Phase 3
• GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)CompletedNCT02666287Phase 1
• Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in CombinationCompletedNCT02064504Phase 1
• A Relative Bioavailability Study of Fluticasone Furoate and LevocabastineCompletedNCT01962467Phase 1
• Relovair PD PK in Chinese Healthy SubjectsCompletedNCT01711463Phase 1
• A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy SubjectsCompletedNCT01691547Phase 1
• A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.CompletedNCT01499446Phase 2
• Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol CombinationCompletedNCT01485445Phase 1
• Rhinitis, Cognition and Driving PerformanceCompletedNCT01318681Not applicable
• Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy SubjectsCompletedNCT01299558Phase 1
• Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an InhalerCompletedNCT01213849Phase 1
• An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to PlaceboWithdrawnNCT01076439Phase 4
• Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese SubjectsCompletedNCT01000597Phase 1
• A Study of GW685698X in Healthy Japanese Male SubjectsCompletedNCT00972673Phase 1
• Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy SubjectsCompletedNCT00538057Phase 1
• Repeat Dose GW685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy VolunteersCompletedNCT00522678Phase 1

← Fluticasone furoate overview